<html>
<head>
<title>Generate Biomedicines raises $370M Series B with a focus on protein-based drugs • TechCrunch</title>
<link href="../Styles/Style.css" type="text/css" rel="stylesheet"/>
</head>
<body>
<h1 class="translated">Generate Biomedicines 募集 3.7 亿美元 B 轮融资，重点是基于蛋白质的药物 TechCrunch</h1>
<blockquote>原文：<a href="https://web.archive.org/web/https://techcrunch.com/2021/11/18/generate-biomedicines-raises-370m-series-b-with-a-focus-on-protein-based-drugs/amp/">https://web.archive.org/web/https://techcrunch.com/2021/11/18/generate-biomedicines-raises-370m-series-b-with-a-focus-on-protein-based-drugs/amp/</a></blockquote><div><div class="content">

			
	
		
		

		
<p class="amp-featured-image translated"><amp-img src="https://web.archive.org/web/20221216004338im_/https://techcrunch.com/wp-content/uploads/2021/11/GettyImages-1271698849.jpg?w=1024" class="attachment-post-thumbnail size-post-thumbnail wp-post-image amp-wp-enforced-sizes i-amphtml-layout-intrinsic i-amphtml-layout-size-defined" alt="" srcset="https://web.archive.org/web/20221216004338im_/https://techcrunch.com/wp-content/uploads/2021/11/GettyImages-1271698849.jpg 8000w, https://web.archive.org/web/20221216004338im_/https://techcrunch.com/wp-content/uploads/2021/11/GettyImages-1271698849.jpg?resize=150,113 150w, https://web.archive.org/web/20221216004338im_/https://techcrunch.com/wp-content/uploads/2021/11/GettyImages-1271698849.jpg?resize=300,225 300w, https://web.archive.org/web/20221216004338im_/https://techcrunch.com/wp-content/uploads/2021/11/GettyImages-1271698849.jpg?resize=768,576 768w, https://web.archive.org/web/20221216004338im_/https://techcrunch.com/wp-content/uploads/2021/11/GettyImages-1271698849.jpg?resize=680,510 680w, https://web.archive.org/web/20221216004338im_/https://techcrunch.com/wp-content/uploads/2021/11/GettyImages-1271698849.jpg?resize=1536,1152 1536w, https://web.archive.org/web/20221216004338im_/https://techcrunch.com/wp-content/uploads/2021/11/GettyImages-1271698849.jpg?resize=2048,1536 2048w, https://web.archive.org/web/20221216004338im_/https://techcrunch.com/wp-content/uploads/2021/11/GettyImages-1271698849.jpg?resize=1200,900 1200w, https://web.archive.org/web/20221216004338im_/https://techcrunch.com/wp-content/uploads/2021/11/GettyImages-1271698849.jpg?resize=50,38 50w" layout="intrinsic" i-amphtml-layout="intrinsic"> <i-amphtml-sizer class="i-amphtml-sizer"> <img alt="" aria-hidden="true" class="i-amphtml-intrinsic-sizer" role="presentation" src=""/> </i-amphtml-sizer> <noscript> <img src="../Images/1170461ea1502a988a1a665b189545c4.png" class="attachment-post-thumbnail size-post-thumbnail wp-post-image" alt="" decoding="async" loading="lazy" srcset="https://web.archive.org/web/20221216004338im_/https://techcrunch.com/wp-content/uploads/2021/11/GettyImages-1271698849.jpg 8000w, https://web.archive.org/web/20221216004338im_/https://techcrunch.com/wp-content/uploads/2021/11/GettyImages-1271698849.jpg?resize=150,113 150w, https://web.archive.org/web/20221216004338im_/https://techcrunch.com/wp-content/uploads/2021/11/GettyImages-1271698849.jpg?resize=300,225 300w, https://web.archive.org/web/20221216004338im_/https://techcrunch.com/wp-content/uploads/2021/11/GettyImages-1271698849.jpg?resize=768,576 768w, https://web.archive.org/web/20221216004338im_/https://techcrunch.com/wp-content/uploads/2021/11/GettyImages-1271698849.jpg?resize=680,510 680w, https://web.archive.org/web/20221216004338im_/https://techcrunch.com/wp-content/uploads/2021/11/GettyImages-1271698849.jpg?resize=1536,1152 1536w, https://web.archive.org/web/20221216004338im_/https://techcrunch.com/wp-content/uploads/2021/11/GettyImages-1271698849.jpg?resize=2048,1536 2048w, https://web.archive.org/web/20221216004338im_/https://techcrunch.com/wp-content/uploads/2021/11/GettyImages-1271698849.jpg?resize=1200,900 1200w, https://web.archive.org/web/20221216004338im_/https://techcrunch.com/wp-content/uploads/2021/11/GettyImages-1271698849.jpg?resize=50,38 50w" sizes="(max-width: 1024px) 100vw, 1024px" data-original-src="https://web.archive.org/web/20221216004338im_/https://techcrunch.com/wp-content/uploads/2021/11/GettyImages-1271698849.jpg?w=1024"/> </noscript> </amp-img></p><p class="translated">图片来源:胡安·盖尔特纳/科学图片库/盖蒂图片社</p><p class="translated"><span data-amp-original-style="font-weight: 400;" class="amp-wp-fe3f5cc">药物开发空间正持续吸引越来越多的投资。周四，另一家主要公司 Generate Biomedicines 宣布进行 3.7 亿美元的 B 轮融资。</span></p>
<p class="translated"><span data-amp-original-style="font-weight: 400;" class="amp-wp-fe3f5cc"> Generate Biomedicines 正在兜售一种基于平台的药物开发方法，但有自己的说法:专注于蛋白质。</span></p>
<p class="translated">Generate 的论点很简单:它的目标不是在目标和自然界中已经存在的蛋白质(或者，最常见的是，在科学数据和文献中)之间建立联系，而是旨在理解大图景——关于蛋白质如何制造以及它们为什么做这些事情(基本上是身体中的一切)的“基本原则”。Generate Biomedicines 的首席执行官迈克·纳利(Mike Nally)告诉 TechCrunch，最终目标是利用这一知识制造新的蛋白质，有朝一日这些蛋白质可以执行“大多数生命功能”。</p>
<p class="translated"><span data-amp-original-style="font-weight: 400;" class="amp-wp-fe3f5cc">在过去的三年里，该公司成功地将这些基本原则付诸实践。</span></p>
<p class="translated">“我们已经能够产生跨越所有蛋白质形态的新蛋白质，因此包括抗体、肽、酶以及细胞和基因治疗，”纳利说。</p>
<p class="translated"><span data-amp-original-style="font-weight: 400;" class="amp-wp-fe3f5cc"> Generate Biomedicines 是旗舰先锋公司培养的</span> <a href="https://web.archive.org/web/20221216004338/https://techcrunch.com/2020/04/02/flagship-pioneering-raises-1-1-billion-to-spend-on-sustainability-and-health-focused-biotech/"> <span data-amp-original-style="font-weight: 400;" class="amp-wp-fe3f5cc">成长骨干</span> </a> <span data-amp-original-style="font-weight: 400;" class="amp-wp-fe3f5cc">中的另一个，旗舰先锋公司是 Moderna 背后的投资者。该公司在 2020 年摆脱了隐身状态，获得了该公司 5000 万美元的初始投资，这与我们在其他旗舰公司看到的情况一致，比如新推出的</span><a href="https://web.archive.org/web/20221216004338/https://techcrunch.com/2021/11/09/flagship-pioneerings-new-venture-is-betting-on-trna-to-treat-thousands-of-diseases/"><span data-amp-original-style="font-weight: 400;" class="amp-wp-fe3f5cc">Alltrna</span></a><span data-amp-original-style="font-weight: 400;" class="amp-wp-fe3f5cc">。</span></p>
<p class="translated">最近一轮融资是 Generate Biomedicines 在外部融资方面的首次重大尝试。该轮将包括 <span data-amp-original-style="font-weight: 400;" class="amp-wp-fe3f5cc">阿拉斯加永久基金、高原生命科学风险投资公司、ARCH Venture Partners 以及 T. Rowe Price Associates，Inc. </span> <span data-amp-original-style="font-weight: 400;" class="amp-wp-fe3f5cc">建议的基金和账户，以及旗舰先锋公司的额外投资。</span></p>
<p class="translated">到目前为止，生成生物医学似乎还没有引起人们的兴趣。</p>
<p class="translated">一方面，该公司可能受益于总体趋势。2019 年至 2020 年间，药物发现领域的风险投资增加了近一倍，达到<a href="https://web.archive.org/web/20221216004338/https://nvca.org/healthcare-innovation/" target="_blank" rel="noopener"><span data-amp-original-style="font-weight: 400;" class="amp-wp-fe3f5cc">【162 亿美元</span> </a> <span data-amp-original-style="font-weight: 400;" class="amp-wp-fe3f5cc">。与此同时，对人工智能药物开发的投资也在不断增加。根据斯坦福大学 2020 年的一份报告，它在 2020 年达到了</span><a href="https://web.archive.org/web/20221216004338/https://aiindex.stanford.edu/wp-content/uploads/2021/03/2021-AI-Index-Report_Master.pdf" target="_blank" rel="noopener"><span data-amp-original-style="font-weight: 400;" class="amp-wp-fe3f5cc"/></a><span data-amp-original-style="font-weight: 400;" class="amp-wp-fe3f5cc">139 亿美元，超过 2019 年资助水平的 4 倍。2021 年 8 月，每份</span> <a href="https://web.archive.org/web/20221216004338/https://www.signifyresearch.net/healthcare-it/total-vc-funding-ai-drug-development-clinical-trials-hits-10-7bn/" target="_blank" rel="noopener"> <span data-amp-original-style="font-weight: 400;" class="amp-wp-fe3f5cc">研究报告</span> </a> <span data-amp-original-style="font-weight: 400;" class="amp-wp-fe3f5cc">的资助已经达到 107 亿美元。</span></p>
<p class="translated">这一轮规模很大，但与今年占据类似领域的公司的数字相差不远:如 Insilico Medicine 的<a href="https://web.archive.org/web/20221216004338/https://techcrunch.com/2021/06/22/a-i-drug-discovery-platform-insilico-medicine-announces-255-million-in-series-c-funding/"><span data-amp-original-style="font-weight: 400;" class="amp-wp-fe3f5cc">【2.55 亿美元的 C 轮</span> </a> <span data-amp-original-style="font-weight: 400;" class="amp-wp-fe3f5cc">，或</span> <a href="https://web.archive.org/web/20221216004338/https://cellarity.com/news/cellarity-raises-123-million-in-series-b-funding-to-pioneer-a-new-approach-to-drug-discovery-treating-disease-at-the-level-of-the-cell-as-opposed-to-a-single-molecular-target" target="_blank" rel="noopener"> <span data-amp-original-style="font-weight: 400;" class="amp-wp-fe3f5cc"> Cellarity 的</span> </a> <span data-amp-original-style="font-weight: 400;" class="amp-wp-fe3f5cc">(另一家旗舰先驱公司)1.23 亿美元的 b 轮</span></p>
<p class="translated"><span data-amp-original-style="font-weight: 400;" class="amp-wp-fe3f5cc"> Generate Biomedicines 的领导层将这一轮的规模归功于该公司对蛋白质生物学和基于蛋白质的药物开发的整体新看法。</span></p>
<p class="translated"><span data-amp-original-style="font-weight: 400;" class="amp-wp-fe3f5cc">治疗性蛋白质，尤其是单克隆抗体，在药物市场中所占的份额越来越大。2018 年，</span> <a href="https://web.archive.org/web/20221216004338/https://www.nature.com/articles/d43747-020-00765-2" target="_blank" rel="noopener"> <span data-amp-original-style="font-weight: 400;" class="amp-wp-fe3f5cc">最畅销的 10 种</span> </a> <span data-amp-original-style="font-weight: 400;" class="amp-wp-fe3f5cc">药物中有 7 种是单克隆抗体。生物过程国际杂志</span><span data-amp-original-style="font-weight: 400;" class="amp-wp-fe3f5cc">2020 年的一份报告发现，在过去五年里，单克隆抗体的全球销售额增长速度超过了所有其他生物药物。</span></p>
<p class="translated"><span data-amp-original-style="font-weight: 400;" class="amp-wp-fe3f5cc">单克隆抗体也许在</span> <a href="https://web.archive.org/web/20221216004338/https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7551545/" target="_blank" rel="noopener"> <span data-amp-original-style="font-weight: 400;" class="amp-wp-fe3f5cc">肿瘤学</span> </a> <span data-amp-original-style="font-weight: 400;" class="amp-wp-fe3f5cc">和免疫学领域最为人熟知。但是用例正在扩展。例如，单克隆抗体，如礼来公司制造的用于治疗新冠肺炎的单克隆抗体，就是一种你可能已经听说过的治疗性蛋白质。</span></p>
<p class="translated"><span data-amp-original-style="font-weight: 400;" class="amp-wp-fe3f5cc"> Generate Biomedicines 专注于所有蛋白质形式，但他们最初专注于开发抗体，最终称其占基于蛋白质的生物治疗市场的约 60%。</span></p>
<p class="translated">尽管如此，产生抗体只是整个过程的一部分。联合创始人兼首席战略创新官莫莉·吉布森补充说，专注于蛋白质功能的基本原则，允许定制蛋白质设计的未开发水平。</p>
<p class="translated"><span data-amp-original-style="font-weight: 400;" class="amp-wp-fe3f5cc">为了把你的头缠在天平上，想想自生命开始以来所有经过自然选择磨练的蛋白质。这些蛋白质只代表了我们生命的组成部分能够形成的全部可能蛋白质的一小部分。</span></p>
<p class="translated">吉布森说:“大自然在生命历史中采样的序列空间总量几乎相当于地球所有海洋中的一滴水。”。</p>
<p class="translated"><span data-amp-original-style="font-weight: 400;" class="amp-wp-fe3f5cc">生成生物医学的方法是使用人工智能来理解我们可能能够制造的其他功能蛋白质，而不是识别尚未开发的现存蛋白质。</span></p>
<p class="translated">也就是说，治疗性蛋白质并不是最容易制造的药物。 <a href="https://web.archive.org/web/20221216004338/https://www.fda.gov/vaccines-blood-biologics/biologics-research-projects/immunogenicity-protein-based-therapeutics" target="_blank" rel="noopener"> <span data-amp-original-style="font-weight: 400;" class="amp-wp-fe3f5cc">从历史上看</span> </a> <span data-amp-original-style="font-weight: 400;" class="amp-wp-fe3f5cc">，免疫系统</span> <a href="https://web.archive.org/web/20221216004338/http://www.iptonline.com/articles/public/IPTTEN79NoPrint.pdf" target="_blank" rel="noopener"> <span data-amp-original-style="font-weight: 400;" class="amp-wp-fe3f5cc">并没有完全接受</span> </a> <span data-amp-original-style="font-weight: 400;" class="amp-wp-fe3f5cc">新的蛋白质。吉布森说，该公司的技术可以绕过这个路障。她说，该公司可以“共同优化”免疫原性和蛋白质功能。</span></p>
<p class="translated">她说:“为了做到这一点，我们开发了一种专有的实验方法来测量和 ML 方法来了解蛋白质是如何被免疫系统识别的，所以我们最终可以避免它。”</p>
<p class="translated"><span data-amp-original-style="font-weight: 400;" class="amp-wp-fe3f5cc">总的来说，Generate Biomedicines 将自己视为药品制造商和平台。纳利说，该公司有几个处于临床前阶段的候选药物(重点是传染病、肿瘤学和免疫学)。目标是在 2023 年前达到新药研究状态。</span></p>
<p class="translated">但是 Generate Biomedicines 最大的好处是，它为其他人提供了一个平台，使基于蛋白质的药物开发过程变得更加顺利。 <span data-amp-original-style="font-weight: 400;" class="amp-wp-fe3f5cc">过去，纳利曾表示，合作伙伴关系将是 Generate Biomedicines 战略的一部分。但到目前为止，该公司尚未披露任何信息。但他补充说，该公司正在寻找在疾病领域有深厚专业知识或在某些目标上有专长的合作伙伴。</span></p>
<p class="translated">有了这轮融资，Generate Biomedicines 计划将其员工人数扩大到 500 人——该公司目前有 80 名员工。该公司还在建设两个设施，以扩展其湿实验室、机器学习和数据生成能力。</p>


		

			
	
		

			<amp-pixel src="https://web.archive.org/web/20221216004338im_/https://ampmetrics.techcrunch.com/pixel.gif" placeholder="" class="i-amphtml-layout-fixed i-amphtml-layout-size-defined" i-amphtml-layout="fixed"/>
		<amp-analytics data-credentials="include" class="i-amphtml-layout-fixed i-amphtml-layout-size-defined" i-amphtml-layout="fixed">
		
	</amp-analytics>
	<amp-pixel src="https://web.archive.org/web/20221216004338im_/https://pixel.wp.com/g.gif?v=ext&amp;blog=136296444&amp;post=2236472&amp;tz=-8&amp;srv=techcrunch.com&amp;host=techcrunch.com&amp;rand=RANDOM&amp;ref=DOCUMENT_REFERRER" class="i-amphtml-layout-fixed i-amphtml-layout-size-defined" i-amphtml-layout="fixed"/><amp-analytics id="tc_googleanalytics" type="googleanalytics" class="i-amphtml-layout-fixed i-amphtml-layout-size-defined" i-amphtml-layout="fixed"/><amp-analytics id="tc_comscore" type="comscore" class="i-amphtml-layout-fixed i-amphtml-layout-size-defined" i-amphtml-layout="fixed"/><amp-analytics id="tc_parsely" type="parsely" class="i-amphtml-layout-fixed i-amphtml-layout-size-defined" i-amphtml-layout="fixed"/>	</div>

</div>    
</body>
</html>